HTLV-1 is the etiological factor of a neurodegenerative disease (HAM/TSP). It is marked by thoracic spinal cord atrophy, where astrocyte and glial cell activation are observed. HAM/TSP is accompanied by alteration in the cerebrospinal fluid (CSF).
We aim at studying whether the alteration in CSF composition impacts impact neural cells transcriptomic.
We will therefore treat glial cells and astrocytes, which have been derived from iPSC by our collaborators at Imagine (Deleidi’s lab), with CSF from HTLV carriers.
